A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
AML
MDS
CMML

Interventions

DRUG: CFI-400945
DRUG: Azacitidine

Sponsor

Treadwell Therapeutics, Inc